Navigation Links
InterMune to Present at Deutsche Bank Biotech Boston Confab
Date:11/7/2008

BRISBANE, Calif., Nov. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Deutsche Bank's 2008 Biotech Boston Confab on November 11, 2008 at 4:00 p.m. EST.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
2. InterMune to Release Third Quarter 2008 Financial Results on November 6
3. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
4. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
5. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
6. InterMune to Present at Canaccord Adams Conference
7. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
8. InterMune to Present at BMO Healthcare Conference
9. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
10. InterMune to Present at Jefferies Healthcare Conference
11. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/3/2016)... Sunnyvale, CA (PRWEB) , ... February 03, 2016 ... ... publisher of remote Linux and Unix visualization solutions today announced the addition of ... Session Preview allows users to see the current state of the remote Linux ...
(Date:2/3/2016)... -- Silk Therapeutics, Inc., today announced the closing of a $6 ... a total of $10.25 million in Series A funding based ... round was led by existing investor The Kraft Group of ... investors Lear Corporation and Highland Consumer Partners, as well as ... Richard Sackler , MD, with Summer Road, LLC; Erin ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... aid in the rapid development and ongoing quality control of molecular assays targeting ... is extremely high,” Dr. Gregory R. Chiklis, President and CEO of ZeptoMetrix, relayed ...
(Date:2/3/2016)... ... February 03, 2016 , ... Marktech Optoelectronics, a ... wafers, and InP epi wafers based in Latham, New York, offers a ... and Avalanche photodiodes–to Si and InGaAs PIN photodiodes. But it is Marktech's newly ...
Breaking Biology Technology:
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
(Date:2/2/2016)... 2016   Parabon NanoLabs (Parabon) announced ... Research Office and the Defense Forensics and Biometrics ... the company,s Snapshot Kinship Inference software ... generally, defense-related DNA forensics.  Although Snapshot is best ... and ancestry from DNA evidence), it also has ...
Breaking Biology News(10 mins):